Indomethacin, a nonsteroidal anti-inflammatory drug, alters the composition of the intestinal microbiota, and the intestinal microbiota affect the pharmacokinetics of indomethacin.

Δ⁹-Tetrahydrocannabinol (THC)-E-gel enables robust preclinical study of voluntary THC consumption in mice, revealing sex-dependent psychotomimetic effects that are valuable for understanding cannabimimetic responses.

The number and effects of mutations leading to full drug resistance crucially determine treatment failure probability and should be used to inform antimicrobial treatment strategies with regard to avoidance of resistance emergence.

The oral carbapenem 'Tebipenem' has high level antibacterial activity against highly drug-resistant Shigella, and its mode of action and pharmacokinetics make it suitable for the treatment of severe diarrhoea caused by highly drug-resistant bacteria.

Pharmacokinetics, the venerable science that measures the dynamics and concentrations an administered drug attains in organs, has been extended to the subcellular level – organelles – by a generalizable new paradigm.

Most chloroquine regimens trialled for the treatment of COVID19 will not result in life-threatening cardiovascular toxicity.

Shortened hepatitis C therapy, with retreatment if needed, can reduce antiviral drug use in patients with mild liver disease, but day 2 viral load is not an adequate predictor of outcome.

After myocardial infarction, gut microbiota affects platelet aggregation rate by regulating the absorption and metabolism of ticagrelor.

Overlaying single cell readouts of cell cycle and apoptosis onto a multidimensional analysis of pulsed cisplatin signalling dynamics reveals targetable mechanisms of platinum resistance in lung adenocarcinoma.

Biological and pharmacokinetic studies indicate that the anti-tubercular drug, delamanid, could be repurposed for the treatment of visceral leishmaniasis.